Johnson & Johnson
The latest news about Johnson & Johnson: headlines, AI summaries and the full story from every source.
- Johnson & Johnson Considering Spin-Off of Hips-and-Knees Business
- Johnson & Johnson Reports Long-Term Efficacy Data for Icotyde in Treating Plaque Psoriasis
- Johnson & Johnson Outperforms Peers Despite Slower Revenue Growth
- Johnson & Johnson Shares Rise on Reported Talks with Apollo for Orthopedics Unit
- Apollo Global Management in Talks to Acquire Johnson & Johnson’s DePuy Synthes Orthopedics Unit
- Johnson & Johnson Considering Sale of DePuy Synthes to Apollo for $20 Billion
- Apollo Global in Talks to Acquire Johnson & Johnson's Orthopedics Unit
- Johnson & Johnson Launches Surgical Robot Ottava in Competitive Robotic Surgery Market
- Johnson & Johnson's Top Investment Among Its Biotech Holdings
- Johnson & Johnson Receives Approval in China for Oral Psoriasis Treatment
- Jim Cramer Analyzes Johnson & Johnson After FDA Approval of OTTAVA Robotic System
- Johnson & Johnson Receives FDA Clearance for Surgical Robot and Targets $100 Billion in Revenue
- Johnson & Johnson Reaches $5.5 Billion Talc Settlement Amid Long-Running Litigation
- Johnson & Johnson Reaches Talc Settlement and Hits Record Highs
- Johnson & Johnson Proposes $5.5 Billion Settlement for Remaining Talc Litigation
- Johnson & Johnson to Pay $5.5 Billion to Settle Talc Baby Powder Lawsuits
- Johnson & Johnson Reaches $5.5 Billion Talc Settlement to Resolve Decade-Long Litigation
- Intuitive Surgical Shares Rise Amid Analyst Support Despite J&J Competition
- Johnson & Johnson Executive Sells Shares Amid Strong Stock Performance
- Johnson & Johnson Is Refocusing Its Business Strategy
- Johnson & Johnson's Oncology Division Drives Growth Amid Dividend Stability
- Johnson & Johnson Receives FDA Approval for New Robotic Surgical System
- DePuy Synthes Acquires Expanding Innovations to Enhance Spine Implant Portfolio
- Johnson & Johnson Declares Quarterly Dividend of $1.34 per Share
- Earnings Season Begins with Key Reports from JPMorgan Chase and Netflix
- Johnson & Johnson Stock Rises After Guggenheim Analyst Raises Price Target
- Johnson & Johnson Invests $1 Billion to Expand Vision Manufacturing in Jacksonville
- Johnson & Johnson to Invest Over $1 Billion in Florida Contact Lens Manufacturing Facility
- Johnson & Johnson Launches New Plaque Psoriasis Treatment Competing with AbbVie’s Skyrizi
- Johnson & Johnson Launches New Plaque Psoriasis Treatment to Challenge AbbVie’s Skyrizi
- Johnson & Johnson Study Shows Earlier Use of Prostate Cancer Drug Improves Outcomes
- Johnson & Johnson vs AbbVie: Divergent Growth Strategies in Q1 2026 Earnings
- Johnson & Johnson Maintains Strong Growth Prospects According to Goldman Sachs
- Johnson & Johnson Hopes New Psoriasis Pill Icotyde Becomes a Major Revenue Driver
- Johnson & Johnson Stock Performance Outpaces Market Amid Strong Q1 Earnings
- Johnson & Johnson Uses AI to Halve Drug Development Lead Time
- Johnson & Johnson Reports 5.3% Sales Growth and $32B Investment in 2025
- Barclays Increases Price Target for Johnson & Johnson Due to Strong Pharma Performance
- Coca-Cola and Johnson & Johnson Report Mixed Financial Results Amid Dividend Streaks
- Johnson & Johnson's Dividend Growth and Operational Streamlining Drive Stock Rally
- Johnson & Johnson Increases Dividend for 64th Consecutive Year